CKO mice display decreased skin barrier function and perturbed homeostasis. by Kevin J. Mills (9270966)

Subjects:

Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts. by Gillian P. McHugo (8965919)

Localization and conditional deletion of C/EBP in SKH1 mouse epidermis. by Kevin J. Mills (9270966)

Subjects:

Distribution of SNPs and their frequencies based on mutation classes. by Sadia Afrin Runa (22504971)

Conditional deletion of C/EBP in epidermis results in downregulation of transcripts and pathways associated with lipid biosynthesis in epidermis. by Kevin J. Mills (9270966)

Subjects:

Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

Correlation between protein abundances and R_5-20 z-score among cases at baseline. Protein abundances, normalized to mean 0 and variance 1, are displayed on the y-axis. (... by Spela Kokelj (8356644)

Table of Bliss synergy scores in KRAS G12C–mutant cell lines treated with AMG 510 and pemigatinib (FGFR inhibitor). by Angela Abdollahi (15166230)

Subjects:

Raw GraphPad Prism graphs with underlying values used for plotted data and measures reported. by Angela Abdollahi (15166230)

Subjects:

Distributions of singscore-based EMT scores for TCGA samples across 32 tumor types using signature genes described in Mak MP, et al. (Clin Cancer Res. 2016;22: 609–620). by Angela Abdollahi (15166230)

Subjects:

<i>FGFR1</i> siRNA knockdown synergizes with KRAS G12C inhibitors in LU99 cells. by Angela Abdollahi (15166230)

Subjects:

Table of MIA PaCa-2–resistant clones and Bliss synergy scores from the combination of AMG 510 and pemigatinib or AMG 510 and an FGFR2/3i. by Angela Abdollahi (15166230)

Subjects:

FGFR1 expression and combination effect with AMG 510 and pemigatinib in MIA PaCa-2–resistant cells. by Angela Abdollahi (15166230)

Subjects:

Tumors from vehicle-treated mice were collected at the end of study, homogenized, and assessed for expression of FGFR1, vimentin, and β-actin. by Angela Abdollahi (15166230)

Subjects:

Cell line characterization and combination effect of KRAS G12C inhibitors and pemigatinib. by Angela Abdollahi (15166230)

Subjects:

In vivo activity of KRAS G12C inhibitors and pemigatinib in the LU99 xenograft model. by Angela Abdollahi (15166230)

Subjects:

Z-score–transformed gene expression data for EMT signature genes (Mak MP, et al. Clin Cancer Res. 2016;22: 609–620). by Angela Abdollahi (15166230)

Subjects:

Table of Bliss synergy scores in KRAS G12C–mutant cells with an epithelial or mesenchymal phenotype treated with the combination of AMG 510 and pemigatinib. by Angela Abdollahi (15166230)

Subjects:

In vivo combination activity of AMG 510 and pemigatinib in epithelial-like or mesenchymal-like phenotype lung cancer PDX models. by Angela Abdollahi (15166230)

Subjects: